STRO
STRO
NASDAQ · Biotechnology

Sutro Biopharma Inc

$10.07
-0.19 (-1.85%)
As of Nov 14, 2:23 AM ET ·
Financial Highlights (FY 2026)
Revenue
192.03M
Net Income
-358,042,066
Gross Margin
—
Profit Margin
-186.5%
Rev Growth
+14.8%
D/E Ratio
4.05
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 66.9% 66.9%
Operating Margin -154.5% -139.1% 4.4% 4.4%
Profit Margin -186.5% -177.1% 3.9% 3.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 192.03M 167.30M 26.00M 21.24M
Gross Profit — — 17.40M 14.21M
Operating Income -296,739,871 -232,676,323 1.13M 924.7K
Net Income -358,042,066 -280,743,909 1.01M 706.3K
Gross Margin — — 66.9% 66.9%
Operating Margin -154.5% -139.1% 4.4% 4.4%
Profit Margin -186.5% -177.1% 3.9% 3.3%
Rev Growth +14.8% +14.8% +22.0% +10.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 64.31M 64.31M 17.53M 15.15M
Total Equity 15.86M 15.86M 104.75M 96.80M
D/E Ratio 4.05 4.05 0.17 0.16
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -283,013,492 -234,241,869 1.64M 1.18M
Free Cash Flow — — 646.8K 654.2K